Drugs in R & D
Công bố khoa học tiêu biểu
* Dữ liệu chỉ mang tính chất tham khảo
Sắp xếp:
Changes in Levels of Biomarkers Associated with Adipocyte Function and Insulin and Glucagon Kinetics During Treatment with Dapagliflozin Among Obese Type 2 Diabetes Mellitus Patients
Drugs in R & D - Tập 16 - Trang 255-261 - 2016
This study aimed to investigate changes in levels of biomarkers associated with
adipocyte function and insulin and glucagon kinetics after a meal tolerance test
(MTT) during treatment with dapagliflozin among obese type 2 diabetes mellitus
(T2DM) patients. T2DM patients with hemoglobin A1c (HbA1c) levels >6.5 % and
body mass index (BMI) >25 kg/m2 were treated with dapagliflozin 5 mg/day for at
lea...
Pharmacokinetics of a New Oral Vitamin D Receptor Activator (2-Methylene-19-Nor-(20S)-1α,25-Dihydroxyvitamin D3) in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism on Hemodialysis
Drugs in R & D - Tập 17 - Trang 597-605 - 2017
2-Methylene-19-nor-(20S)-1α,25-dihydroxyvitamin D3 (DP001 or 2MD) is a novel,
potent 1α-hydroxylated vitamin D analog that binds to the vitamin D receptor and
suppresses parathyroid hormone synthesis and secretion with potential for an
improved safety profile compared to existing active vitamin D analogs. The
purpose of this study was to evaluate the pharmacokinetics of DP001 given orally
after he...
Population Pharmacokinetics and Pharmacodynamics of GSK961081 (Batefenterol), a Muscarinic Antagonist and β2-Agonist, in Moderate-to-Severe COPD Patients: Substudy of a Randomized Trial
Drugs in R & D - Tập 15 - Trang 281-291 - 2015
GSK961081 (batefenterol) is a novel bifunctional molecule composed of a
muscarinic antagonist and a β2‐agonist. The aims of this substudy were (1) to
characterize the population pharmacokinetics (PK) and pharmacodynamics (PD) of
GSK961081 in patients with moderate-to-severe chronic obstructive pulmonary
disease (COPD); and (2) to investigate the relationship between systemic
exposure to GSK961081 ...
Six-Month Toxicity Study of Oral Administration of D-003 in Sprague Dawley Rats
Drugs in R & D - Tập 3 - Trang 375-386 - 2012
Background: D-003 is a mixture of high molecular weight aliphatic primary acids
purified from sugarcane wax (Saccharum officinarum) having cholesterol-lowering
and antiplatelet effects. Aim: This study was undertaken to investigate the
toxicity induced by long-term oral administration of D-003 for 6 months to
Sprague Dawley rats of both sexes. Methods: Rats were randomly divided into four
groups (...
Neoadjuvant Dose-Dense Gemcitabine plus Docetaxel and Vinorelbine plus Epirubicin for Operable Breast Cancer
Drugs in R & D - Tập 11 - Trang 147-157 - 2012
Background: Neoadjuvant anti-tumor activity of an alternating taxane- and
anthracycline-based dose-dense regimen in patients with operable,
noninflammatory large breast cancer was investigated. Objective: The objective
is to study the rate of pathological complete response in patients with breast
cancer receiving dose-dense chemotherapy sequentially with gemcitabine plus
docetaxel and vinorelbine ...
Transmucosal Delivery of Nicotine in Combination with Tincture of Benzoin Inhibits Apoptosis
Drugs in R & D - Tập 17 - Trang 615-621 - 2017
The aim of this study was to test the hypothesis that tincture of benzoin (TOB)
facilitates immediate transmucosal nicotine absorption while simultaneously
promoting a safe and sustained delivery of the nicotine. In combination with
TOB, nicotine toxicity and diffusion across human mucosal cells were measured
using a 3-D human mucosal tissue model. Nicotine was delivered 2.1 times more
quickly in ...
WF 10
Drugs in R & D - Tập 5 - Trang 242-244 - 2012
WF 10 [TCDO, Oxoferin®, Immunokine™, Macrokine™] is a 1 : 10 dilution of
tetrachlorodecaoxide formulated for IV delivery. It was developed by Oxo Chemie
in Switzerland as an adjunctive therapy to combination antiretroviral and
opportunistic infection prophylaxis regimens in AIDS patients. WF 10
specifically targets macrophages. Oxo Chemie has worldwide patent rights to WF
10 and Dimethaid Research...
Efficacy and Tolerability of Hyaluronan (ialuset®) in the Treatment of Pressure Ulcers
Drugs in R & D - Tập 8 - Trang 267-273 - 2012
Background: Pressure ulcers are complex chronic wounds and a frequent cause of
morbidity in elderly subjects in hospitals and nursing homes. Local treatment is
based on the use of dressings that protect the wound and provide a favourable
environment for healing to occur. ialuset®, a treatment based on hyaluronan
(hyaluronic acid), is already available on the market and known to be an
effective tre...
Tổng số: 809
- 1
- 2
- 3
- 4
- 5
- 6
- 10